ClinicalTrials.gg
CompletedNCT06854952FALCONUpdated Aug 10, 2026Results posted

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

A Phase 2 interventional study of TERN-601 and Matching Placebo in Overweight or Obesity, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Obesity by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Obesity · Merck & Co., Inc.

Enrollment
12th of 15
167 · median 497
Started
2025
the only one that year
Phase 2
7 of 17
none open now
Registered
17th of 17
by date

Among the 17 studies in Obesity by Merck & Co., Inc, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, and was the 17th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 17 studies in Obesity by Merck & Co., Inc is open now. The open studies under Obesity, anywhere →

Where they have run

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Obesity by Merck & Co., Inc as a file.
02

Study summary

This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

Keywords

  • overweight
  • obesity
  • obese
  • glucagon-like peptide-1 receptor agonist
  • GLP-1 receptor agonist
  • GLP-1
04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 167 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

First submitted before Terns, Inc. became part of Merck & Co., Inc.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Female or male aged 18 to 75 years
  2. (BMI) of:

    1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2

      OR

    2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
  3. \< 6.5%
  4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)

Key Exclusion Criteria:

  1. Have diabetes mellitus
  2. Have obesity induced by medication or other diagnosed endocrinologic disorders
  3. Have had or are planning surgical treatment or device-based therapy for obesity
  4. Lifetime history of suicide attempt
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    TERN-601 250 mg

    Orally administered once daily.

    Drug: TERN-601

  • Experimental
    TERN-601 500 mg (slow titration)

    Orally administered once daily.

    Drug: TERN-601

  • Experimental
    TERN-601 500 mg

    Orally administered once daily.

    Drug: TERN-601

  • Experimental
    TERN-601 750 mg

    Orally administered once daily.

    Drug: TERN-601

  • Placebo comparator
    Matching Placebo

    Orally administered once daily.

    Other: Matching Placebo

Interventions

  • DrugTERN-601

    Investigational drug

  • OtherMatching Placebo

    Matching placebo

07

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight

    Percent change (%) in body weight from baseline to Week 12

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Body Weight (kg)

    Change in body weight (kg) from baseline to Week 12

    Time frame: 12 weeks

  2. ≥ 5% Weight Loss

    Participants achieving ≥ 5% weight loss

    Time frame: 12 weeks

08

Results

Posted Aug 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneTERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching Placebo
Started3334343333
Completed2428282927
Not completed96646
Withdrew: Adverse event30221
Withdrew: Lost to follow-up12113
Withdrew: Investigator discretion01001
Withdrew: Pregnancy10000
Withdrew: Withdrawal by subject33111
Withdrew: Prohibited medication00100
Withdrew: Other: subject was discontinued due to positive urine drug screen per sponsor guidance10000
Withdrew: Other: withdrawn from study due to +drug test00100

Outcome measures

PrimaryPercent Change in Body Weight

Percent change (%) in body weight from baseline to Week 12

Time frame:
12 weeks
Reported as:
Least squares mean · Percent Change (%)
Percent Change in Body Weight
Percent Change (%)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching Placebo
Percent Change in Body Weight-2.11 ± 0.688-3.85 ± 0.687-4.87 ± 0.688-3.31 ± 0.688-0.30 ± 0.701
Statistical analysis
  • TERN-601 250 mg vs Matching Placebo · ANOVA · p = 0.0561 · Lsm difference: -1.81 · 90% CI -3.4 to -0.3
  • TERN-601 500 mg (Slow Titration) vs Matching Placebo · ANOVA · p = 0.0002 · Lsm difference: -3.55 · 90% CI -5.1 to -2.0
  • TERN-601 500 mg vs Matching Placebo · ANOVA · p = <0.0001 · Lsm difference: -4.58 · 90% CI -6.1 to -3.0
  • TERN-601 750 mg vs Matching Placebo · ANOVA · p = 0.0016 · Lsm difference: -3.01 · 90% CI -4.6 to -1.5
SecondaryChange in Body Weight (kg)

Change in body weight (kg) from baseline to Week 12

Time frame:
12 weeks
Reported as:
Least squares mean · kg
Change in Body Weight (kg)
kgTERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching Placebo
Change in Body Weight (kg)-2.23 ± 0.733-4.02 ± 0.735-4.97 ± 0.735-3.60 ± 0.740-0.45 ± 0.746
Statistical analysis
  • TERN-601 250 mg vs Matching Placebo · ANCOVA · p = 0.0718 · Lsm difference: -1.78 · 90% CI -3.4 to -0.2
  • TERN-601 500 mg (Slow Titration) vs Matching Placebo · ANCOVA · p = 0.0004 · Lsm difference: -3.57 · 90% CI -5.2 to -2.0
  • TERN-601 500 mg vs Matching Placebo · ANCOVA · p = <0.0001 · Lsm difference: -4.52 · 90% CI -6.1 to -2.9
  • TERN-601 750 mg vs Matching Placebo · ANCOVA · p = 0.0016 · Lsm difference: -3.15 · 90% CI -4.8 to -1.5
Secondary≥ 5% Weight Loss

Participants achieving ≥ 5% weight loss

Time frame:
12 weeks
Reported as:
Count of participants · Participants
≥ 5% Weight Loss
ParticipantsTERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching Placebo
≥ 5% Weight Loss4 (5.2 to 30.8)11 (23.8 to 56.5)13 (30.1 to 63.4)7 (12.4 to 41.9)4 (5.4 to 31.8)
Statistical analysis
  • TERN-601 250 mg vs Matching Placebo · Cochran-Mantel-Haenszel · p = 0.9054 · Risk difference (rd): -0.6 · 90% CI -17.9 to 16.5
  • TERN-601 500 mg (Slow Titration) vs Matching Placebo · Cochran-Mantel-Haenszel · p = 0.0700 · Risk difference (rd): 23.9 · 90% CI 3.8 to 42.4
  • TERN-601 500 mg vs Matching Placebo · Cochran-Mantel-Haenszel · p = 0.0104 · Risk difference (rd): 31.0 · 90% CI 10.4 to 49.3
  • TERN-601 750 mg vs Matching Placebo · Cochran-Mantel-Haenszel · p = 0.4019 · Risk difference (rd): 9.6 · 90% CI -9.0 to 27.7

Adverse events

Collected over From enrollment until end of follow-up (Week 16). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TERN-601 250 mg0/33 (0%)0/33 (0%)23/33 (69.7%)
TERN-601 500 mg (Slow Titration)0/34 (0%)0/34 (0%)25/34 (73.5%)
TERN-601 500 mg0/34 (0%)1/34 (2.9%)27/34 (79.4%)
TERN-601 750 mg0/33 (0%)2/33 (6.1%)26/33 (78.8%)
Matching Placebo0/33 (0%)0/33 (0%)17/33 (51.5%)
Most frequent serious events
Most frequent serious events
EventTERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching Placebo
AppendicitisInfections and infestations0/330/340/341/330/33
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders0/330/340/341/330/33
Drug-induced liver injuryHepatobiliary disorders0/330/341/340/330/33
Most frequent other events
Showing 10 of 85
Most frequent other events
EventTERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching Placebo
NauseaGastrointestinal disorders16/3317/3422/3420/333/33
VomitingGastrointestinal disorders2/3310/3413/3411/330/33
ConstipationGastrointestinal disorders2/332/348/344/331/33
DizzinessNervous system disorders1/333/347/342/330/33
DiarrhoeaGastrointestinal disorders4/334/344/341/332/33
HeadacheNervous system disorders4/330/343/342/331/33
DyspepsiaGastrointestinal disorders2/330/343/343/332/33
EructationGastrointestinal disorders3/330/343/340/330/33
FatigueGeneral disorders1/333/343/342/330/33
Gastrooesophageal reflux diseaseGastrointestinal disorders1/330/342/342/331/33

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching PlaceboTotal
<=18 years000000
Between 18 and 65 years2831292929146
>=65 years5354421
Age, Continuous
Age, Continuous(Years)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching PlaceboTotal
Mean47.6 ± 15.8748.1 ± 13.3353.6 ± 11.4350.5 ± 13.8251.2 ± 12.9350.2 ± 13.56
Sex: Female, Male
Sex: Female, Male(Participants)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching PlaceboTotal
Female2627272626132
Male7777735
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching PlaceboTotal
American Indian or Alaska Native120003
Asian001001
Native Hawaiian or Other Pacific Islander000000
Black or African American551010838
White2626232224121
More than one race000000
Unknown or Not Reported110114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching PlaceboTotal
Hispanic or Latino971191147
Not Hispanic or Latino2427232422120
Unknown or Not Reported000000
Weight (kg)
Weight (kg)(kg)TERN-601 250 mgTERN-601 500 mg (Slow Titration)TERN-601 500 mgTERN-601 750 mgMatching PlaceboTotal
Mean99.63 ± 18.64399.46 ± 16.690100.22 ± 16.702101.84 ± 18.35999.68 ± 20.768101.16 ± 18.075
09

Study locations

17 sites
  • FALCON Research Site
    Birmingham, Alabama 35294, United States
  • FALCON Research Site
    Homewood, Alabama 35209, United States
  • FALCON Research Site
    Tucson, Arizona 85712, United States
  • FALCON Research Site
    Spring Valley, California 91978, United States
  • FALCON Research Site
    Port Orange, Florida 32127, United States
  • FALCON Research Site
    Louisville, Kentucky 40213, United States
  • FALCON Research Site
    Marrero, Louisiana 70072, United States
  • FALCON Research Site
    Boston, Massachusetts 02114, United States
  • FALCON Research Site
    Rochester, Minnesota 55905, United States
  • FALCON Research Site
    City of Saint Peters, Missouri 63303, United States
  • FALCON Research Site
    Beachwood, Ohio 44122, United States
  • FALCON Research Site
    Medford, Oregon 97504, United States
  • FALCON Research Site
    Dallas, Texas 75230, United States
  • FALCON Research Site
    Houston, Texas 77079, United States
  • FALCON Research Site
    San Antonio, Texas 78229, United States
  • FALCON Research Site
    St. George, Utah 84790, United States
  • FALCON Research Site
    Arlington, Virginia 22206, United States
10

References and documents

Publications

  • Garvey WT, Rosenstock J, Bays HE, Denham D, Kohli A, Haines M, Jones C, Kwan E, Castelloe E, Marmon T, Kuriakose E, Nelson C. Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. Obesity (Silver Spring). 2026 Jul 30. doi: 10.1002/oby.70271. Online ahead of print. PubMed 42528333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2025, 5 months.

Results were first posted in Aug 2026, 11 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartActual
Mar 7, 2025
Primary completionActual
Aug 19, 2025
CompletionActual
Sep 19, 2025
Results first posted
Aug 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06854952
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Mar 7, 2025
Primary completion
Aug 19, 2025
Completion
Sep 19, 2025
Results posted
Aug 10, 2026
Last update
Aug 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion